top of page

For all cataract surgeons managing glaucoma patients

The world’s first, IOL-mounted, controlled release drug delivery platform capable of delivering multiple years of therapy

CONSISTENT DAILY RELEASE

Targeting 3-year delivery of bimatoprost to treat glaucoma in patients undergoing cataract surgery

Dual pads securely attached to each haptic are designed to elute treatment continuously for multiple years. 

The SpyGlass Pharma™ Drug Delivery Platform has not been approved by the FDA

spyglass_lineart_v4.jpg

Directly addressing an unmet need

Patient non-adherence to their glaucoma medication can lead to complications, disease progression and vision loss. Methods of drug delivery independent of patient behavior is an industry-wide need.

adherence2.jpg

Millions of glaucoma patients undergo cataract surgery each year

SpyGlass Pharma-Eyecelerator AAO 2022[17]_r1 [Slide 7].png

INNOVATIVE PLATFORM

Explore the pioneering technology behind the SpyGlass Pharma™ Drug Delivery Platform

VERSATILE PLATFORM

Designed to deliver multiple drugs to address additional ophthalmic indications

spyglass_IOL_inserted.jpg

The device you know coupled with treatment you trust. All within the same procedure you know by heart.

The SpyGlass Pharma™ Drug Delivery Platform is Implanted with the IOL into the capsular bag using surgical techniques identical to standard cataract procedures. 

Intraocular drug delivery that lasts

Learn more about SpyGlass Pharma™ 

texture_bg.jpg

SpyGlass Pharma™ Completes Enrollment in Phase I/II Study of its Promising Long-Term Drug Delivery Platform for Glaucoma and Ocular Hypertension

ALISO VIEJO, Calif., November 19, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, today announced completion of enrollment in its Phase I/II, randomized, multi-center, controlled clinical trial (NCT06120842) evaluating SpyGlass’ Drug Delivery Platform in patients with glaucoma or ocular hypertension. The SpyGlass platform is designed to deliver multiple years of bimatoprost to lower intraocular pressure (IOP) and is implanted during routine cataract surgery. (View full press release)

Spyglass Pharma Logo - Long - Black_edited.png

Tel: 949-284-6904

27061 Aliso Creek Rd, Suite 100
Aliso Viejo, CA 92656

SUBSCRIBE

Sign up to receive SpyGlass Pharma™ news and updates.

Thanks for submitting!

© 2024 SpyGlass Pharma™. All Rights Reserved.

Follow us on LinkedIn

  • LinkedIn
bottom of page